Johnson & Johnson’s Cordis Corporation said on Friday that Britain’s leading private health insurance group had decided to reimburse its drug-coated coronary stents.
The Cypher stent, which releases sirolimus to prevent restenosis, was introduced in April following CE market approval but is not yet widely used in Britain’s state-funded National Health Service.
Cordis said in a statement that people insured privately with BUPA, which has 2.8 million members, could now be treated with the new technology, significantly reducing the potential need for repeat hospital visits for additional angioplasty or more costly surgery.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!